National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med1995; 333: 1581–1587.
2.
CampbellBC.Hyperacute ischemic stroke care-current treatment and future directions. Int J Stroke2024; 19: 718–726.
3.
AlamowitchSTurcGPalaiodimouL, et al. European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke. Eur Stroke J2023; 8: 8–54.
4.
MuirKW.Should we switch to tenecteplase for all ischemic strokes? Evidence and logistics. Int J Stroke2025; 20: 261–267.
5.
MuirKWFordGAFordI, et al. Tenecteplase versus alteplase for acute stroke within 4.5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial. Lancet Neurol2024; 23: 1087–1096.
6.
YogendrakumarVCampbellBChurilovL, et al. Extending the Time Window for Tenecteplase by Effective Reperfusion of Penumbral Tissue in Patients with Large Vessel Occlusion (ETERNAL-LVO): rationale and design of a multicenter, prospective, randomized, open-label, blinded-endpoint, controlled phase 3 trial. Int J Stroke2025; 20: 367–372.
7.
KimJOlaiyaMTDe SilvaDA, et al. Global stroke statistics 2023: availability of reperfusion services around the world. Int J Stroke2024; 19: 253–270.
8.
TunklCAgarwalARamageE, et al. Telemedicine networks for acute stroke: an analysis of global coverage, gaps, and opportunities. Int J Stroke2025; 20: 297–309.
9.
DekkerLMoudrousWDaemsJD, et al. Prehospital stroke detection scales: a head-to-head comparison of 7 scales in patients with suspected stroke. Int J Stroke2025; 20: 268–277.
10.
PirlogBOJacobAPRajanSS, et al. Outcomes of patients with pre-existing disability managed by mobile stroke units: a sub-analysis of the BEST-MSU study. Int J Stroke2023; 18: 1209–1218.
11.
FatimaNSaqqurMHussainMSShuaibA.Mobile stroke unit versus standard medical care in the management of patients with acute stroke: a systematic review and meta-analysis. Int J Stroke2020; 15: 595–608.
12.
DagonnierMDonnanGADavisSMDeweyHMHowellsDW.Acute stroke biomarkers: are we there yet. Front Neurol2021; 12: 619721.
13.
ElsherifSLegereBMohamedA, et al. Beyond conventional imaging: a systematic review and meta-analysis assessing the impact of computed tomography perfusion on ischemic stroke outcomes in the late window. Int J Stroke2025; 20: 278–288.
14.
ScheldemanLSenersPWoutersA, et al. Early penumbral FLAIR changes predict tissue fate in patients with large vessel occlusions. Int J Stroke2025; 20: 310–318.
15.
FerroJMBendszusMJansenO, et al.; RE-SPECT CVT Study Group. Recanalization after cerebral venous thrombosis. A randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous and dural sinus thrombosis. Int J Stroke2022; 17: 189–197.
16.
MaHGuYBianT, et al. Dabigatran etexilate versus warfarin in cerebral venous thrombosis in Chinese patients (CHOICE-CVT): an open-label, randomized controlled trial. Int J Stroke2024; 19: 635–644.
17.
BrakelBARebchukADOspelJ, et al. International practice patterns and perspectives on endovascular therapy for the treatment of cerebral venous thrombosis. Int J Stroke2025; 20: 319–327.
18.
CoutinhoJMVan de MunckhofAAguiar de SousaD, et al. Reducing the global burden of cerebral venous thrombosis: an international research agenda. Int J Stroke2024; 19: 599–610.
19.
AbdelmassihYMauget-FaÿsseMSenersP, et al. Early reperfusion in patients with acute retinal artery occlusion: a multicenter prospective study. Int J Stroke2025; 20: 338–346.
20.
ShahjoueiSBavarsad ShahripourRDumitrascuOM.Thrombolysis for central retinal artery occlusion: an individual participant-level meta-analysis. Int J Stroke2024; 19: 29–39.
21.
PoliSGrohmannCWenzelDA, et al. Early REperfusion therapy with intravenous alteplase for recovery of VISION in acute central retinal artery occlusion (REVISION): study protocol of a phase III trial. Int J Stroke2024; 19: 823–829.
